News & Analysis on Clinical Trial Services & Contract Research And Development
Amgen: Rodeo Therapeutics acquisition
By Jenni Spinner
- Last updated on
Amgen has agreed to acquire Rodeo Therapeutics, a pharma firm specializing in small-molecule therapies intended to promote regeneration and repair of tissues. Under terms of the agreement, Amgen will acquire all outstanding shares for $55m upfront, and future contingent milestone payments potentially worth up $666m.
“Given the encouraging preclinical data to date, we are excited about the opportunity to develop a novel therapy with potential in a range of important inflammatory disease indications," said Raymond Deshaies, senior vice president of global research at Amgen.